Canine neurotensin, neurotensin6-13 and neuromedin N: primary structures and receptor activity

A novel form of neurotensin post-translationally modified by arginylation

A novel bioactive form of neurotensin post-translationally modified at a Glu residue was isolated from porcine intestine. Purification of the peptide was guided by detection of intracellular Ca2+ release in SK-N-SH neuroblastoma cells. Using high resolution accurate mass analysis on an ion trap Fourier transform mass spectrometer, the post-translational modification was identified as arginine linked to the gamma-carboxyl of Glu via an isopeptide bond, and we named the newly identified peptide "arginylated neurotensin" (R-NT, N-(neurotensin-C5-4-yl)arginine). Although arginylation is a known modification of N-terminal amino groups in proteins, its presence at a Glu side chain is unique. The finding places neurotensin among the few physiologically active peptides that occur both in post-translationally modified and unmodified forms. Pharmacologically, we characterized R-NT for its ligand activity on three known neurotensin receptors, NTR1, -2, and -3, and found that R-NT has similar pharmacological properties to those of neurotensin, however, with a slightly higher affinity to all three receptors. We expressed the intracellular receptor NTR3 as a soluble protein secreted into the cell culture medium, which allowed characterization of its R-NT and neurotensin binding properties. The creation of soluble NTR3 also provides a potential tool for neutralizing neurotensin action in vivo and in vitro. We have shown that SK-N-SH neuroblastoma cells express NTR1 and NTR3 but not NTR2, suggesting that the Ca2+ mobilization elicited by R-NT is via NTR1.

Distribution of neurotensin-containing neurons in the central nervous system of the pigeon and the chicken

Neurotensin is widely located in neurons of the central and peripheral nervous systems among mammalian species. To obtain a comparative evaluation, we examined the distribution of neurotensin-containing cell bodies and fibers in the central nervous system of the pigeon and the chicken. The pattern of localization of neurotensin immunoreactivity was similar in the two species. Abundant accumulations of neurotensin-containing cell bodies were found in the dorsolateral corticoid area, the piriform cortex, the parahippocampal area, the medial part of the frontal neostriatum, the lateral part of the caudal neostriatum, nucleus accumbens, the bed nucleus of the stria terminalis, ventral paleostriatum, the preoptic area, the ventromedial hypothalamic nucleus, the inferior hypothalamic nucleus, the infundibular hypothalamic nucleus, and the mammillary nuclei. Extremely dense networks of neurotensin-containing fibers were found in the pallial commissure, the lateral septal nucleus, the preoptic area, the periventricular gray around the third ventricle, the dorsalis hypothalamic area, the hypothalamic nuclei, the parabrachial nucleus, the locus ceruleus, and the dorsal vagal complex. Major differences of immunoreactivity between the two species were as follows. 1) The chicken neurohypophysis contained an extremely large accumulation of immunoreactive fibers, but there were few in the median eminence. The reverse was found in the pigeon. 2) The optic tectum in the pigeon contained immunoreactive cells and fibers in layers 2 and 4, but no immunoreactivity was seen in the chicken optic tectum. 3) The cerebellar cortex in the pigeon contained a small number of immunoreactive fibers, whereas that in the chicken did not. 4) The pigeon spinal cord contained immunoreactive neurons in the subependymal layer, but the chicken spinal cord did not. Our observations suggest the presence of a very wide network of neurotensin-containing neurons in the avian brain and spinal cord, which is also the case in mammals.

Distribution of neurotensin-containing neurons in the central nervous system of the dog

The distribution of neurotensin-containing cell bodies and fibers was examined in the central nervous system of the dog using light microscopic immunohistochemistry. A very large population of neurotensin-containing cell bodies was observed in the septal nuclei, nucleus accumbens septi, preoptic areas, bed nucleus of the stria terminalis, olfactory tubercle, entorhinal cortex, ventral subiculum, anterodorsal thalamic nucleus, anteroventral thalamic nucleus, nucleus reuniens, lateral habenular nucleus, parabrachial nucleus, and nucleus of the solitary tract. Extremely dense networks of neurotensin-containing fibers were found in the globus pallidus, hypothalamus, infundibular stalk, ventral tegmental area, periaqueductal gray, interpeduncular nucleus, and spinal nucleus of the trigeminal nerve and substantia gelatinosa. However, the cerebral neocortex and cerebellum were negative for neurotensin in the present study. When the present findings are compared with those in other animals, it is clear that the major species-specific differences in distribution involve three immunonegative regions and four immunopositive regions in the dog: The former are the cerebral neocortex, mammillary body, and hippocampus; the latter are the cell bodies in the pyramidal layer of the olfactory tubercle, the superficial and middle layers of the entorhinal cortex and ventral subiculum, and the nerve fibers in the interpeduncular nucleus. The present study indicates a rather extensive network of neurotensin neurons in the central nervous system of the dog.

The pharmacology of neurotensin analogues on neurones in the rat substantia nigra, pars compacta in vitro

The effects of neurotensin and neurotensin analogues on dopamine neurones were studied in an in vitro slice preparation of rat substantia nigra, pars compacta using extracellular and intracellular recording techniques. Neurotensin had an EC50 of 13 nM in these experiments. This study showed that the C-terminal 5 amino acids of neurorotensin in neurotensin-(9-13) retained agonist activity on substantia nigra neurones. The naturally occurring neurotensin analogues neuromedin N and avian neurotensin were also active whilst kinetensin was inactive. Kinetensin differs from the C-terminal neurotensin 5-amino acids by two amino acids. The difference between the activity of neurotensin and the inactivity of kinetensin was investigated using synthetic peptides which contained single amino acid substitutions. These results show that position 12 of neurotensin is important for agonist activity in the substantia nigra.

Co-occurrence of gamma-aminobutyric acid, parvalbumin and the neurotensin-related neuropeptide LANT6 in pallidal, nigral and striatal neurons in pigeons and monkeys

Immunohistochemical double-labeling techniques were used to examine the co-localization of the neurotransmitter gamma-aminobutyric acid (GABA), the calcium-binding protein parvalbumin and the neurotensin-related hexapeptide LANT6 in neurons of the striatum and its target areas in pigeons and monkeys. The studies revealed the existence of a population of striatal interneurons apparently containing all three of these substances in both monkeys and pigeons. The results also revealed that GABA and LANT6 were co-localized in numerous pallidal and nigral reticulata neurons that also contained parvalbumin in both species. Examination of diverse other cell groups in avian forebrain and midbrain revealed that parvalbumin and LANT6 were typically co-localized to GABAergic neurons. In light of the presence of pallidal, reticulata and striatal neurons containing these three substances in two widely divergent amniote groups such as pigeons and monkeys, it seems likely that: (1) comparable neuronal populations are present in other avian and mammalian species; and (2) these neuronal populations play a fundamental role in basal ganglia functions that requires these three substances.

Induction of the neurotensin (NT) gene in PC12 cells gives rise to NT precursor (approximately 88%), NT(3-13)-like peptide (approximately 10%), and NT (approximately 2%)

Neurotensin (NT) is coexpressed with catecholamines in sympathetic neurons and adrenal chromaffin cells. A pheochromocytoma PC12 cell line can also be induced to express the NT gene and produce immunoreactive NT. In the present study, NT mRNA was quantified under various hormonal conditions and NT precursor synthesis rates were determined by pulse labeling and immunoprecipitation. In addition, NT precursor and NT-related products were measured using RIA and were characterized using HPLC and Sephadex chromatography. Neurotensin mRNA, NT precursor synthesis, and NT precursor/product levels were correlated. Surprisingly, NT appeared to be a minor product, both in cells and media: NT precursor (approximately 88%), NT(3-13)-like peptide (approximately 10%), and NT (approximately 2%). Neurotensin added to cultures was not converted to NT(3-13). Treatment of cells with 60 mM KCl or various secretagogues induced Ca(2+)-dependent release of NT precursor, NT(3-13), and NT in proportion to their cellular contents. These results suggest a) that NT precursor processing in induced PC12 cells was much slower than NT precursor synthesis, b) that NT(3-13) was a major product and NT a minor one, and c) that NT precursor and its products were stored within secretory vesicles.

Research note: cardiovascular effects of neurotensin in anesthetized White Leghorn hens

Solutions of neurotensin (NT) at 0, 12, 60, 120, and 600 nM were infused i.v. into anesthetized, 16- to 34-wk-old hens at 60 microL/kg per minute for 30 min. These infusates increased plasma NT concentrations to steady state values of about .1, .2, 1, 2, and 10 times the postprandial concentrations of NT in hepatic portal blood, respectively. None of these concentrations significantly affected heart rate or arterial (carotid) or central venous (jugular) blood pressure.

Tissue-specific processing of neurotensin/neuromedin-N precursor in cat

Antisera were raised towards the putative N-terminal sequence of the canine precursor to neurotensin (NT) and neuromedin N (NMN), residues 24-35 in the pre-prohormone, as well as its C-terminal TAIL, residues 164-170. These were used in conjunction with previously developed immunoassays towards NT and NMN to characterize the precursor and to study its processing in feline brain, heart, adrenal and intestine. The precursor was identified as a 18 kDa protein that reacted with both the N- and C-terminal antisera and yielded NT3-13 and NT4-13 upon treatment with pepsin. It represented 5-10% of the NT activity in ileum. Processing was found to be tissue-specific, yielding primarily NT, NMN and TAIL in most tissues but also giving rise to N-terminally extended forms of these peptides, which were particularly evident in extracts of adrenal and intestine. Two of the four molecular forms detected using the TAIL immunoassay were tenatively identified as NT-TAIL and Gly-Ser-Tyr-Tyr-Tyr based upon chromatographic evidence. Western blotting indicated that ileal extracts contained large molecular forms of NT (17 kDa) and NMN (16 kDa), whereas brain extracts contained primarily the N-terminal of the precursor without NT and NMN attached (14.3 kDa). It was concluded that the structure of the feline precursor in its N- and C-terminal regions, and the positioning of the signal peptide cleavage site were as predicted from cDNA work in the dog. On the other hand, processing of the precursor was complex, occurring in a tissue-specific manner.

Isolation and quantitation of several new peptides from the canine neurotensin/neuromedin N precursor

Using antisera towards the bioactive peptides, neurotensin and neuromedin N, as well as towards the N-terminal and C-terminal regions of their shared 170-residue precursor, peptides representing various portions of the precursor were isolated from extracts of canine ileum. In total, seven peptides were isolated, two of which had not been previously identified. One was the C-terminal tail of the precursor (Gly-Ser-Tyr-Tyr-Tyr) and the other was the tail peptide extended N-terminally to include neurotensin (Glp-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu-Lys-Arg-Gly-Ser-Tyr -Tyr- Tyr). By comparing the measured concentrations for each of the identified peptides, it was established that processing at the three Lys-Arg cleavage sites within the precursor did not occur to the same extent. Cleavage at the N-terminus of neuromedin N was approximately 10% complete, that between neurotensin and the tail was approximately 90% complete, and that between neuromedin N and neurotensin was approximately 95% complete. Three immunoreactive proteins were also identified by immunochemical and chromatographic analyses: N-terminally extended neuromedin N (125 residues), N-terminally extended neurotensin (140 residues), and the entire 147-residue precursor. It was concluded that neurotensin, tail and large molecular neuromedin N were the primary products of processing for this precursor in canine ileum, while minor products included neuromedin N, neurotensin tail, and large molecular neurotensin.

Pepsin-mediated processing of synthetic precursor-like sequence yields neurotensin-like peptide

A 15 amino acid synthetic peptide, which spanned the dibasic cleavage site C-terminal to neurotensin (NT), in its 170-residue canine precursor, was synthesized by solid-phase methods. Using this substrate in combination with a radioimmunoassay specific for the C-terminal region of NT, a simple assay was developed to monitor protease-mediated cleavage of the Leu8-Lys9 bond in the substrate. Hog pepsin and the related enzymes, rhizopus pepsin, bovine cathepsin D, and mouse renin, were found to be effective in this assay, pepsin cleaving only this bond to liberate the NT-like sequence. The pH dependence of the reaction indicated that pepsin, cathepsin D, and renin exhibited significant activity at pH's characteristic for secretory vesicles (pH 5.5-6.5). In addition, pepsin and cathepsin D were shown to process the native precursor at pH's as high as 5.5. These results, although not proof, are consistent with the idea that endoproteases with pepsin-like specificity may be involved in the processing of the NT precursor in neural/endocrine cells.

Rapid degradation of neurotensin by stimulated rat mast cells

A RIA towards neurotensin (NT) using C-terminal- and N-terminal-specific antisera was used to study degradation of this tridecapeptide by isolated rat mast cells. Incubation of NT (10 microM) with peritoneal or pleural mast cells resulted in a rapid loss of NT immunoreactivity (iNT), as measured by C-terminal-directed antiserum, with little effect on N-terminal iNT. The rate of the reaction was faster with pleural cells (T1/2, 30 s) than with peritoneal cells (T1/2, 180 s) and was greater than 10-fold slower in the presence of metabolic poisons. The enzyme(s) involved is most likely released from the cells during secretion, as NT was degraded by media conditioned by compound 48/80-stimulated mast cells 40-60 times faster than by media from unstimulated cells. This degradation by conditioned media was concentration dependent, pH dependent, and temperature sensitive. HPLC analyses indicated a near stoichiometric conversion of NT to NT(1-12) (66%) and NT(1-11) (34%) after incubation for 10-30 s with conditioned media. By 30 min only NT(1-11) and NT(1-10) were present. Phenanthroline (1 mM), an inhibitor of carboxypeptidase, prevented the loss of C-terminal iNT and the generation of NT(1-12) and NT(1-11). While NT(1-12) was effective in releasing histamine from mast cells in vitro and increasing vascular permeability in vivo, NT(1-11) was not. These results suggest that carboxypeptidase-like enzyme(s) could modulate the level and form of NT-related peptides in various states involving activation of mast cells.

Neuromedin-N inhibits migrating myoelectric complex and induces irregular spiking in the small intestine of rats; comparison with neurotensin

The effects of neuromedin-N on migrating myoelectric complexes in the small intestine of rats were studied. As neuromedin-N and neurotensin are structurally related peptides a comparison with neurotensin was made. Myoelectric activity was recorded by means of three bipolar electrodes implanted into the wall of the small intestine at 5, 15 and 25 cm distal to the pylorus. The peptides were administered as intravenous infusions to fasted conscious rats. Neuromedin-N at doses of 100-800 pmol kg-1 min-1 caused a dose-dependent disruption of the migrating myoelectric complexes and induced irregular spiking activity (n = 7, P less than 0.05). Neurotensin induced a similar response, but at doses of 1.0-8.0 pmol kg-1 min-1 (n = 5, P less than 0.05). Thus, on a molar basis, neuromedin-N appeared to be about 100-times less potent than neurotensin. Hexamethonium (20 mg kg-1 i.v.) inhibited the migrating motor complexes and induced quiescence, but did not block the effect of neuromedin-N at a dose of 800 pmol kg-1 min-1. Atropine (1 mg kg-1 i.v.) and mepyramine (2 mg kg-1 i.v.) did not affect the migrating motor complexes, nor did they block the effect of neuromedin-N. Simultaneous infusion of neuromedin-N and neurotensin in a 1:1 molar ratio at doses of 2 pmol kg-1 min-1 showed inhibition of the response to neurotensin in eight out of ten experiments. In conclusion, neuromedin-N changes the myoelectric activity in the small intestine from a fasting to a fed pattern.(ABSTRACT TRUNCATED AT 250 WORDS)

Characterization of neurotensin(6-13) from an hepatic fibrolamellar carcinoma

Neurotensin(6-13) has been isolated and sequenced as the major form of neurotensin-like immunoreactivity (NTLI) in a human hepatic fibrolamellar carcinoma. Circulating NTLI in the patient, especially C-terminal, was very high. In additional studies, NT(6-13) was synthesized and compared with the purified tumor NTLI by HPLC analysis and by testing stability in plasma in vitro. These methods confirmed that the tumor NTLI was identical to NT(6-13). Since the metabolic clearance rate of synthetic NT(6-13) in sheep was 30-fold higher than NT(1-13), it suggests that the elevated plasma levels are the result of impaired clearance and/or markedly elevated production.

Xenopsin-related peptide(s) are formed from xenopsin precursor by leukocyte protease(s) and cathepsin D

Lysates of isolated rat polymorphonuclear leukocytes and macrophages were found to generate xenopsin-related peptides when incubated with a liver extract used as a source of precursor. The lysosomal enzyme, cathepsin D, was also shown to display this property and to share with the lysate a similar pH dependence (optimum, approximately pH 3.5) and sensitivity to the acid protease inhibitor, pepstatin A (ID50: lysate, 10 nM; cathepsin D, 30 nM). When subjected to HPLC on mu-Bondapak C-18, the xenopsin-related peptides generated by the lysate eluted near to those formed by cathepsin D and when tested in a radioreceptor assay for neurotensin, they displayed similar cross-reactivities (peak 2, approximately 50%; peak 1, approximately 100%). These results indicate that cathepsin D from lysed granulocytes can process precursor protein(s) to form radioreceptor-active xenopsin-related peptides.